✦ LIBER ✦

A phase 3 trial of extended release oral dalfampridine in multiple sclerosis

✍ Scribed by Andrew D. Goodman; Theodore R. Brown; Keith R. Edwards; Lauren B. Krupp; Randall T Schapiro; Ron Cohen; Lawrence N. Marinucci; Andrew R. Blight; on behalf of the MSF204 Investigators

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 372 KB
Volume: 68
Category: Article
ISSN: 0364-5134
DOI: 10.1002/ana.22240

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Guidelines for clinical trials of new th

Guidelines for clinical trials of new therapeutic agents in multiple sclerosis: Reporting extended results from phase III clinical trials

✍ D. E. Goodkin; S. Reingold; W. Sibley; J. Wolinsky; H. McFarland; D. Cookfair; F 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 2 views

Biased assessment of blinding in a rando

Biased assessment of blinding in a randomized placebo-controlled trial of oral methotrexate in chronic progressive multiple sclerosis

✍ D. W. J. Dippel; P. G. Oomes; L. H. Visser 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

Antibody-mediated suppression of Vβ5.2/5

Antibody-mediated suppression of Vβ5.2/5.3+ T cells in multiple sclerosis: Results from an MRI-monitored phase II clinical trial

✍ Joep Killestein; Tomas Olsson; Erik Wallström; Anders Svenningsson; Mohsen Khade 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB 👁 1 views

A multicenter, randomized, double-blind,

A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. Oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease

✍ Arnold E. Postlethwaite; Weng Kee Wong; Philip Clements; Soumya Chatterjee; Barr 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 244 KB 👁 1 views